V. Guagnano

发表

Entry into a New Class of Protein Kinase Inhibitors by Pseudo Ring Design.

P. Furet, M. Lang, T. Meyer, 2008 .

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Joseph Schoepfer, Joerg Kallen, Pascal Furet, 2019, ChemMedChem.

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23‐mediated hypophosphatemic rickets

W. Sellers, F. Hofmann, N. Hynes, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.

P. Furet, P. Imbach, M. Lang, 2004, Journal of medicinal chemistry.

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, F. Blasco, G. Caravatti, 2016, Bioorganic & medicinal chemistry letters.

Tandem Inter [4 + 2]/Intra [3 + 2] Cycloadditions of Nitroalkenes. 15. The Bridged Mode (α-Tether)

S. Denmark, A. Stolle, V. Guagnano, 1997 .

Tandem Inter [4 + 2]/Intra [3 + 2] Cycloadditions. 6. The Bridged Mode

S. Denmark, A. Stolle, V. Guagnano, 1995 .

1-Ethoxy-2-nitroethylene and Aluminum Derivatives: A Useful Choice for the Synthesis of Polyunsaturated Nitro Compounds.

V. Guagnano, C. Malanga, R. Menicagli, 1993 .

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Doriano Fabbro, Pascal Furet, Giorgio Caravatti, 2013, Bioorganic & medicinal chemistry letters.

Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2007, Bioorganic & Medicinal Chemistry Letters.

One-pot synthesis of 2-alkyltetrahydropyran-3-ones from 3-nitro-5,6-dihydro-4H-pyran and grignard reagents

S. Samaritani, V. Guagnano, R. Menicagli, 1995 .

Studies on the reduction and hydrolysis of nitroso acetals

S. Denmark, V. Guagnano, J. Vaugeois, 2001 .

REGIOSELECTIVE NI(II)-ASSISTED ALKYLATION OF 2-METHOXY-5,6-DIHYDRO-2H-PYRAN : A NEW ROUTE TO 2-N.ALKYL-5,6-DIHYDRO-2H-PYRANS

V. Guagnano, C. Malanga, R. Menicagli, 1998 .

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

David M. Thomas, W. Sellers, K. Venkatesan, 2012, Cancer discovery.

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Pascal Furet, C. Schnell, J. Brueggen, 2011, Journal of medicinal chemistry.

Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.

Jeffrey A. Porter, W. Sellers, Christopher J. Wilson, 2012, Cancer discovery.

Fibroblast Growth Factor Receptors as Novel Therapeutic Targets in SNF5-Deleted Malignant Rhabdoid Tumors

W. Sellers, C. Roberts, A. Kauffmann, 2013, PloS one.

Synthesis and biological evaluation of highly potent analogues of epothilones B and D.

K. Altmann, G. Bold, G. Caravatti, 2000, Bioorganic & medicinal chemistry letters.

Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.

Pascal Furet, Guido Bold, P. Furet, 2006, Journal of medicinal chemistry.

BET bromodomain inhibitors regulate keratinocyte plasticity

Mathias Frederiksen, H. Ruffner, T. Bouwmeester, 2021, Nature Chemical Biology.

Entry into a new class of protein kinase inhibitors by pseudo ring design.

P. Furet, M. Lang, T. Meyer, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Philipp Holzer, P. Furet, P. Chène, 2016, Bioorganic & medicinal chemistry letters.

The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition

P. Furet, P. Chène, T. Schmelzle, 2022, ChemMedChem.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Philipp Holzer, P. Furet, S. Ferretti, 2018, Bioorganic & medicinal chemistry letters.

Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748]

D. Fabbro, J. Hamon, P. Furet, 2013 .

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

C. Schnell, P. Furet, S. Jeay, 2016, Bioorganic & medicinal chemistry letters.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

David M. Thomas, W. Sellers, K. Venkatesan, 2012, Cancer discovery.

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Philipp Holzer, P. Furet, P. Chène, 2019, ChemMedChem.